💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Haleos Labs Limited, formerly, SMS Lifesciences India Limited, is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, steadily growing business, fully valued.
SMS Lifesciences is scored on the pharma / healthcare framework. It keeps a slim 5.3% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 2.09× reported profit. Free cash flow is worth about -4.7% of its market value.
Over the last 3 years revenue compounded at 2%/yr and profit at 16%/yr. Book value has grown 7%/yr. Return on equity is a modest 8.1%. In the latest quarter profit grew 441% versus the prior quarter.
At 24× earnings, the stock sits at the 63rd percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~14%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 28.78 | — | — |
| P/B | 2.06 | 4.1 | better |
| EV/EBITDA | 12.15 | 19.33 | better |
| ROE | 8.11 | — | — |
| ROCE | 9.76 | 14.41 | worse |
| ROA | 3.36 | 1.64 | better |
| Quick Ratio | 0.53 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue declined 4% in the latest year — a break from prior trajectory. 2% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
Profit is growing faster than revenue (16% vs 2%) — margin expansion is at work.
Operating margin has expanded from 5% to 8% — the business is keeping more of each rupee earned.
ROE at 8% — modest; the capital isn't working hard.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 15% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 2.1× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate fading — recent quarters 15% below earlier ones.
Profit jumped 441% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (8% → 3%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 72.1% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.